DK2964255T3 - Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) - Google Patents
Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) Download PDFInfo
- Publication number
- DK2964255T3 DK2964255T3 DK14708308.3T DK14708308T DK2964255T3 DK 2964255 T3 DK2964255 T3 DK 2964255T3 DK 14708308 T DK14708308 T DK 14708308T DK 2964255 T3 DK2964255 T3 DK 2964255T3
- Authority
- DK
- Denmark
- Prior art keywords
- iri
- prevention
- treatment
- reperfusion injury
- ischemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13158478 | 2013-03-08 | ||
PCT/EP2014/054489 WO2014135694A1 (en) | 2013-03-08 | 2014-03-07 | Treatment and prevention of remote ischemia-reperfusion injury |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2964255T3 true DK2964255T3 (da) | 2021-02-08 |
Family
ID=47833003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14708308.3T DK2964255T3 (da) | 2013-03-08 | 2014-03-07 | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) |
Country Status (11)
Country | Link |
---|---|
US (2) | US10286047B2 (da) |
EP (1) | EP2964255B1 (da) |
JP (2) | JP6636334B2 (da) |
KR (1) | KR102403299B1 (da) |
CN (1) | CN105188750A (da) |
AU (1) | AU2014224599B2 (da) |
CA (1) | CA2901225C (da) |
DK (1) | DK2964255T3 (da) |
ES (1) | ES2844189T3 (da) |
HK (1) | HK1216607A1 (da) |
WO (1) | WO2014135694A1 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2683397B1 (en) | 2011-03-09 | 2017-08-09 | CSL Behring GmbH | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
JP6636334B2 (ja) | 2013-03-08 | 2020-01-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 遠隔虚血再灌流傷害の治療および予防 |
NZ719724A (en) * | 2013-11-22 | 2022-08-26 | Takeda Pharmaceuticals Co | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
PL3157548T3 (pl) | 2014-06-18 | 2022-01-17 | Csl Behring Gmbh | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
MA43270A (fr) * | 2015-11-19 | 2021-06-02 | Takeda Pharmaceuticals Co | Inhibiteur de la c1 estérase humaine recombinante et ses utilisations |
WO2017173494A1 (en) | 2016-04-06 | 2017-10-12 | Csl Limited | Method of treating atherosclerosis |
CN109562149A (zh) | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
JP7330893B2 (ja) | 2017-03-10 | 2023-08-22 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 |
US11865137B2 (en) | 2017-11-03 | 2024-01-09 | The University Of North Carolina At Chapel Hill | Sulfated oligosaccharides having anti-inflammatory activity |
WO2019113642A1 (en) * | 2017-12-15 | 2019-06-20 | Csl Limited | Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
JP2021528421A (ja) | 2018-06-20 | 2021-10-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 細胞保護の方法と組成物 |
CN108852308B (zh) * | 2018-06-22 | 2021-03-30 | 苏州高新区人民医院 | 一种基于多参数影像技术优化检测体系的超时间窗ais临床再灌注方法 |
WO2020210491A1 (en) * | 2019-04-10 | 2020-10-15 | Pantheryx, Inc. | Methods and compositions for reducing gut ischemia/reperfusion-induced injury |
WO2021097345A1 (en) * | 2019-11-13 | 2021-05-20 | The University Of North Carolina At Chapel Hill | Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5714358A (en) | 1980-07-02 | 1982-01-25 | Toray Industries | Antithrombus medical material |
US4383219A (en) | 1980-08-19 | 1983-05-10 | Indiana University Foundation | Nuclear magnetic resonance spatial mapping |
DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
CA2082643A1 (en) | 1990-05-10 | 1991-11-11 | Jan H. Nuijens | Inhibitors of factor xii activation and applications thereof |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
DE4244735A1 (de) | 1992-08-24 | 1994-03-31 | Behringwerke Ag | Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
AU678064B2 (en) * | 1993-09-01 | 1997-05-15 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Method to reduce myocardial injury during acute myocardial infarction |
CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
WO1997007731A2 (en) | 1995-08-18 | 1997-03-06 | Brigham And Women's Hospital, Inc. | Line scan diffusion imaging |
DE19903693A1 (de) | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
US5674236A (en) | 1996-04-30 | 1997-10-07 | Medtronic, Inc. | Lancet for capillary puncture blood samples |
JPH11209399A (ja) | 1997-11-20 | 1999-08-03 | Asahi Chem Ind Co Ltd | 高比重リポ蛋白質を有効成分とする医薬組成物 |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1216052A1 (en) | 1999-09-16 | 2002-06-26 | Byk Gulden Lomberg Chemische Fabrik GmbH | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
JP2001276217A (ja) | 2000-04-04 | 2001-10-09 | Dountsuendorufaa Udo | 単一又は複数の疾患のある患者での組織、血漿又は血液透析用のバイオコートされた吸着剤 |
CA2405709A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
CN1568166A (zh) | 2001-10-15 | 2005-01-19 | 荷姆泰克股份有限公司 | 预防再狭窄的涂层支架 |
CN100455275C (zh) | 2002-02-06 | 2009-01-28 | 祥丰医疗有限公司 | 包覆有可促进内皮细胞的黏附和分化的包衣的医疗装置 |
AU2003215119B2 (en) | 2002-02-11 | 2008-11-20 | Gold-T Tech, Inc. | Method for preventing thrombus formation |
IL163586A0 (en) | 2002-02-21 | 2005-12-18 | Quark Biotech Inc | Methods of preventing or treating brain ischemia or brain injury |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
CA2511125A1 (en) | 2002-12-20 | 2004-07-08 | Axis-Shield Diagnostics Limited | Detection or determination of variants of factor xiia |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
JP2006518749A (ja) | 2003-02-21 | 2006-08-17 | タノックス インコーポレーテッド | 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法 |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
DK2298347T3 (da) | 2003-05-06 | 2016-01-11 | Biogen Hemophilia Inc | Koagulationsfaktor kimære proteiner til behandling af en hæmostatisk lidelse |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7544853B2 (en) | 2003-05-16 | 2009-06-09 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
US20050059660A1 (en) | 2003-08-01 | 2005-03-17 | Pharmacia & Upjohn Company | Novel combination |
US7550263B2 (en) | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
ES2387028T3 (es) | 2003-12-31 | 2012-09-12 | Merck Patent Gmbh | Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
MX2007006997A (es) | 2004-12-23 | 2007-10-10 | Csl Behring Gmbh | Prevencion de formacion y/o estabilizacion de trombo. |
AU2006327989B2 (en) | 2005-12-21 | 2012-06-07 | Pharming Intellectual Property Bv | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury |
US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
JP2009531367A (ja) | 2006-03-31 | 2009-09-03 | アデノバイオ エヌ.フェー. | 診断および治療のためのアデノシンおよびイノシンを組み合わせて使用する組成物、方法およびキット |
GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
PL2698166T3 (pl) | 2006-10-10 | 2016-03-31 | Regenesance B V | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
PE20081834A1 (es) | 2006-12-31 | 2009-01-16 | Boehringer Ingelheim Int | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos |
US20100119512A1 (en) | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
EP2526962B1 (en) | 2007-02-12 | 2019-08-14 | CSL Behring GmbH | Therapeutic application of Kazal-type serine protease inhibitors |
EP2222707B1 (en) | 2007-11-21 | 2016-01-06 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
WO2010049423A1 (en) | 2008-10-27 | 2010-05-06 | Life Sciences Research Partners Vzw | Effects of nitric oxide inhalation on long-term myocardial reperfusion injury |
US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
CN106432503B (zh) | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | 共价双抗体及其用途 |
US20120100140A1 (en) | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
EP3708581A3 (en) | 2009-05-27 | 2021-10-20 | Takeda Pharmaceutical Company Limited | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
EP2683397B1 (en) | 2011-03-09 | 2017-08-09 | CSL Behring GmbH | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
CA2841185C (en) | 2011-07-22 | 2021-05-25 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
EP2758076B1 (en) | 2011-09-24 | 2018-12-12 | CSL Behring GmbH | Combination therapy using immunoglobulin and c1-inhibitor |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
PL2946206T3 (pl) * | 2013-01-20 | 2019-07-31 | Dyax Corp. | Ocena, testy i leczenie zaburzeń mediowanych przez PKAL |
JP6636334B2 (ja) | 2013-03-08 | 2020-01-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 遠隔虚血再灌流傷害の治療および予防 |
ES2897746T3 (es) | 2013-06-28 | 2022-03-02 | Csl Behring Gmbh | Terapia combinada con un inhibidor del Factor XII y un inhibidor de C1 |
WO2017173494A1 (en) | 2016-04-06 | 2017-10-12 | Csl Limited | Method of treating atherosclerosis |
-
2014
- 2014-03-07 JP JP2015560714A patent/JP6636334B2/ja active Active
- 2014-03-07 DK DK14708308.3T patent/DK2964255T3/da active
- 2014-03-07 CN CN201480012556.0A patent/CN105188750A/zh active Pending
- 2014-03-07 EP EP14708308.3A patent/EP2964255B1/en active Active
- 2014-03-07 KR KR1020157028040A patent/KR102403299B1/ko active IP Right Grant
- 2014-03-07 AU AU2014224599A patent/AU2014224599B2/en active Active
- 2014-03-07 CA CA2901225A patent/CA2901225C/en active Active
- 2014-03-07 US US14/773,020 patent/US10286047B2/en active Active
- 2014-03-07 WO PCT/EP2014/054489 patent/WO2014135694A1/en active Application Filing
- 2014-03-07 ES ES14708308T patent/ES2844189T3/es active Active
-
2016
- 2016-04-14 HK HK16104303.6A patent/HK1216607A1/zh unknown
-
2019
- 2019-03-20 US US16/359,598 patent/US10973891B2/en active Active
- 2019-09-20 JP JP2019170986A patent/JP2020007362A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20150128888A (ko) | 2015-11-18 |
JP2020007362A (ja) | 2020-01-16 |
CA2901225A1 (en) | 2014-09-12 |
US20160008442A1 (en) | 2016-01-14 |
EP2964255A1 (en) | 2016-01-13 |
JP2016511267A (ja) | 2016-04-14 |
CA2901225C (en) | 2023-09-19 |
CN105188750A (zh) | 2015-12-23 |
WO2014135694A1 (en) | 2014-09-12 |
US10286047B2 (en) | 2019-05-14 |
JP6636334B2 (ja) | 2020-01-29 |
ES2844189T3 (es) | 2021-07-21 |
HK1216607A1 (zh) | 2016-11-25 |
EP2964255B1 (en) | 2020-11-04 |
US20190269766A1 (en) | 2019-09-05 |
US10973891B2 (en) | 2021-04-13 |
AU2014224599B2 (en) | 2018-11-08 |
AU2014224599A1 (en) | 2015-08-20 |
KR102403299B1 (ko) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2964255T3 (da) | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) | |
DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3129018T3 (da) | Behandling af NAFLD og NASH | |
DK3155024T3 (da) | Opholdsstrukturer og relaterede fremgangsmåder | |
DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
DK3035955T3 (da) | Sammensætning og vaccine til behandling af lungekræft | |
DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
DK3043784T3 (da) | Arylethere og anvendelser deraf | |
DK2882496T3 (da) | Behandling og diagnosticering af melanom | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
DK3021838T3 (da) | Behandling af fedme | |
DK3238707T3 (da) | Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet | |
DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3033081T3 (da) | Sammensætninger og fremgangsmåder til behandling af kronisk urticaria | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK2854910T3 (da) | Ceramidniveauer i behandling og forebyggelse af infektioner | |
DK3205683T3 (da) | Sammensætninger og indretninger af poly-4-hydroxybutyrat |